First U.S. approval of tDCS-based depression treatment

• The U.S. approved a first-of-its-kind tDCS-based treatment for depression.¹
• The milestone is relevant to neuromodulation and device regulation for transcranial stimulation.¹
• It is a tier-1 regulatory signal for non-invasive neuromodulation devices.^{1 1}

Gardner updates

• A systematic review and meta-analysis of randomized clinical trials found efficacy and safety of home-based tDCS in patients with depressive disorders (Nature). ²
• At-home neuromodulation feasibility is supported by RCT-level evidence and informs regulatory and deployment decisions. ²

Weekly enrichment (2026-07-20)

• On Dec 8, 2025 the U.S. FDA granted premarket approval (PMA) to Flow Neuroscience’s transcranial direct current stimulation (tDCS) device for moderate-to-severe major depressive disorder (MDD) in patients aged 18+, as monotherapy or adjunct, in people not considered treatment-refractory to medication.³⁴
• This is the first FDA premarket approval for a home-use, non-invasive brain-stimulation device specifically indicated to treat depression.³⁴
• The FL-100 headset delivers low-intensity direct current to the prefrontal cortex (dorsolateral prefrontal cortex), a region often hypoactive in depression.⁵
• Approval evidence includes a randomized, double-blind, sham-controlled trial published in Nature Medicine; active tDCS produced remission and response rates roughly 2-3x higher than sham.⁵
• In the pivotal trial, 58% of actively treated participants achieved remission by week 10, with symptom reductions appearing as early as 3 weeks.⁵
• The device carries no boxed warning; reported adverse effects were mild and transient, and it was approved under FDA product code JXK.³⁵
• Flow cited real-world data from more than 55,000 users across Europe, the UK, Switzerland, and Hong Kong, reporting 77% seeing improvement within about 3 weeks (company-reported, not peer-reviewed); U.S. availability was expected by mid-2026.⁵
• Commentary authors (Bikson, Brunoni, George in Brain Stimulation) frame the clearance as a regulatory milestone that opens the path to additional home-based neuromodulation indications and technologies.³⁴

Footnotes

1. https://news.google.com/rss/articles/CBMivAFBVV95cUxNZzhJdW1ZQjJIOVdWQ2RjVVdpbFBKVGdRRnphcUNJQUVMX3hiR1RyMmU3YlhVaGxKclBsZVRiMlhnbVM4SzB5alFDSndGYUR4c0hyS3ROVFFGWldCZER1SFAtT0dLQ25TZ3JaN1VZQnBxbk5oS2c3ZzBPd09yazZBQ3NHeEluekw0aW9Ib09ubDJqd25UYnpvcUcyNzAxbHpCMDRmUEs0eEpYeW1qSlVqUmIyNGt0UWV4Z20xMA?oc=5 ↩ ↩² ↩³ ↩⁴

2. https://news.google.com/rss/articles/CBMiX0FVX3lxTE4zUjRFek9lYUhDZ1dpRkVfWVl5ZGlUVEFBeTBzMFhkQlJwb0NxOGZzektuNWw2SEdIamVrbjcxQ0ZpZkcxemhKVUtfXzl0WWh3eUV4bjQzVUJSN3lPT3dR?oc=5 ↩ ↩²

3. https://www.sciencedirect.com/science/article/pii/S1935861X25004231 ↩ ↩² ↩³ ↩⁴

4. https://pubmed.ncbi.nlm.nih.gov/41475514/ ↩ ↩² ↩³

5. https://www.hmpgloballearningnetwork.com/site/pcn/news/fda-approves-first-home-tdcs-treatment-major-depressive-disorder ↩ ↩² ↩³ ↩⁴ ↩⁵